摘要
目的基于胶质细胞增殖调控因子bFGF/TGF-β1探讨逍遥散治疗抑郁症的机制。方法采用CUMS方法建立抑郁症小鼠模型。造模成功后,给予逍遥散和盐酸氟西汀干预,对小鼠体重、摄食量、行为学进行评估;采用Elisa、免疫组化和Western blotting方法检测小鼠前额皮质bFGF和TGF-β1蛋白表达情况及逍遥散的调节作用。结果模型组小鼠体重、饮食情况、糖水摄入量较正常组小鼠出现显著降低(P<0.01),强迫游泳不动时间显著延长(P<0.01),经逍遥散和氟西汀治疗以后得到显著改善(P<0.05);另外Elisa、免疫组化和western blot实验结果均表明,抑郁症小鼠前额皮质bFGF蛋白含量表达显著降低(P<0.01),经逍遥散和氟西汀治疗后,抑郁症小鼠前额皮质bFGF蛋白表达情况可被扭转(P<0.05),而各组小鼠前额皮质TGF-β1蛋白表达情况与bFGF刚好相反。结论逍遥散可通过调控AST抑制剂TGF-β1和促活化剂bFGF而发挥治疗抑郁症的作用,其机制可能与逍遥散通过bFGF/TGF-β1调控前额皮质AST功能有关。
Objective To explore the mechanism of Xiaoyao Powder in treating depression based on glial cell proliferation regulator bFGF/TGF-β1.Methods A mouse model of depression was established using a chronic unpredictable mild stress method.After successful modeling,Xiaoyao Powder and fluoxetine hydrochloride were given to evaluate the body weight,food intake and behavior.Elisa,immunohistochemistry and Western blotting were used to detect the expression of bFGF and TGF-β1 proteins in prefrontal cortex of mice and the regulatory effects of Xiaoyao Powder.Results Compared with the normal group,the body weight,food intake,and syrup preference of the model group decreased significantly(P<0.01),forced swimming immobility time was significantly prolonged(P<0.01),and significantly improved after treatment with Xiaoyao Powder and fluoxetine(P<0.05).In addition,the results of Elisa,immunohistochemistry and western blot showed that the content and expression of bFGF protein in the prefrontal cortex of the model group were significantly decreased(P<0.01),Xiaoyao Powder and fluoxetine treatment can significantly reverse the expression of bFGF protein in prefrontal cortex of depressed mice(P<0.05).However,the expression of TGF-β1 protein in the prefrontal cortex of each group was just the opposite of bFGF.Conclusion Xiaoyao Powder can play a role in the treatment of depression by regulating AST inhibitor TGF-β1 and activator bFGF.The mechanism may be related to Xiaoyao Powder’s regulation of prefrontal cortex AST function through bFGF/TGF-β1.
作者
刘燕
吴耀松
杨铁柱
白娟
寇美静
史占江
陈玉龙
Liu Yan;Wu Yaosong;Yang Tiezhu;Bai Juan;Kou Meijing;Shi Zhanjiang;Chen Yulong(Academy of Chinese Medical Sciences,Henan University of Chinese Medicine,Henan Key Laboratory of TCM Prescription and Syndrome Signaling,Zhengzhou 450046,China;School of Basic Medicine,Henan University of Chinese Medicine,Zhengzhou 450046,China;Luoyang Zhenggu Hospital of Henan Province,Henan Provincial Orthopedic Hospital,Zhengzhou 450016,China;Graduate School,Henan University of Chinese Medicine,Zhengzhou 450046,China;School of Basic Medicine,Hubei University of Chinese Medicine,Wuhan 430065,China)
出处
《世界科学技术-中医药现代化》
CSCD
北大核心
2020年第9期3288-3293,共6页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
河南省科技厅河南省重点研发与推广专项(科技攻关)(202102210026):逍遥散对肝郁脾虚证大鼠下丘脑能量代谢干预作用及分子机制,负责人:刘燕
河南中医药大学博士科研基金(BSJJ2018-03):基于文献计量学的近十年中医学博士学位论文分析,负责人:刘燕
2018年湖北省教育厅科学研究计划指导性项目(B2018100):逍遥散对抑郁症肝郁脾虚证大鼠海马TPH2,IDO1的作用机理,负责人:寇美静。
关键词
抑郁症
逍遥散
前额皮质
BFGF
TGF-Β1
AST
Liver stagnation and spleen deficiency syndrome
Xiaoyao Powder
Prefrontal cortex
bFGF
TGF-β1
AST